Axial Involvement in Psoriatic Arthritis: Dr. Eric Ruderman Perspective
Dr. Eric Ruderman, Chicago, IL., provides his perspective on ACR 2020 coverage of axial involvement in Psoriatic Arthritis. During his remarks, he discusses ACR abstracts #0344, #1372, #2025 and #0505.
Non-radiographic axSpa ACR Abstracts: Dr. Rachel Tate
Dr. Rachel Tate discusses abstracts #0876 and #0448 presented at the ACR20 annual meeting.
Here is the last of our QD Clinics in Podcast form, just before we start ACR2020 coverage.
In this compilation from the past week we talk about
- HIV and arthritis
- Hyperuricemia in PsA
- An odd kind of dermatomyositis
- Running out of options in Difficult RA
Listen here or on your podcast program in your car.
Dr. John Cush RheumNow
5 years 11 months ago
Check out our "Virtual ACR2020 Playbook" to plan how you will take in and consume ACR20 from home and in your fuzzy slippers. https://t.co/5bsOFFXEMZ
Dr. John Cush RheumNow
5 years 11 months ago
Spanish cross-sectional study of 2,102 Rheumatic patients compared meds to COVID risk and showed Denosumab (0.58), zoledronate (0.62), calcium were negatively associated with COVID-19. Why? is it that they are less "sick"? https://t.co/BNbwsCz0rA
Dr. John Cush RheumNow
5 years 11 months ago
Eosinophilia in #RA is either due to a secondary problem (endemic parasitosis, drug hypersensitivity, etc) or may be associated with more severe RA - it is not associated with extraarticular manifestations of RA. https://t.co/J9rOA3cWC4
Pearls from the Virtual ACR20 Playbook: Dr. Meral El Ramahi
Dr. El Ramahi reviews pearls in the RheumNow virtual ACR playbook.
If you need a plan for this weekend's ACR meeting, check out and download our latest, "Virtual ACR 2020 Playbook". The playbook covers: setting virtual learning goals, sessions you probably shouldn't miss, how to still have peer interactions, what to do if you only have time to "dabble' - and more.
Dr. John Cush RheumNow
5 years 11 months ago
Presented at EADV Dermatology Congress - Mirikizumab, IL-23 inhibitor, shown superior to placebo & Secukinumab in Psoriasis. 465 patients given either PBO, MIR (2 doses) or SEC. Wk 52 MIR PASI90 PASI 90 (81%) vs SEC 69% https://t.co/EBCBUjkyWG
The risk of serious infections (SIE) in RA patients given anti-TNF (TNFi) therapy is not static, instead it has been shown to be greatest in the first 6 months of use according to a recent report in Rheumatology.
Dr. John Cush RheumNow
5 years 11 months ago
Racial/ethnic minorities with rheumatic Dz(RD) & COVID had increased odds of hospitalization & ventilatory support. 1,324 pts w/ RD+COVID, 36% hospitalized, 6% died. Compared to whites- Blacks Latinos & Asians had higher risk of hospital (OR=2.7, 1.7, 2.7) https://t.co/OGmarAfzLM
QD Clinic - Another Kind of Dermatomyositis
MDA5 myositis reviewed
QD Clinic - Hyperuricemia in PsA
Possibilities with hyperuricemia in Psoriatic Arthritis
Dr. John Cush RheumNow
5 years 11 months ago
Cohort study (n 186) from NYC shows that patients with COVID and autoimmune disease were not at an increased risk for a ICU admission, intubation, or death (adjOR 0.79, 95%CI 0.37-1.67). AI pts had more comorbidities (26% vs. 13%), immunosuppressives https://t.co/TMCcKbns0f
